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Background: Patients with idiopathic pulmonary fibrosis (IPF) present an important ventilatory
limitation reducing their exercise capacity. Non-invasive ventilatory support has been shown to
improve exercise capacity in patients with obstructive diseases; however, its effect on IPF
patients remains unknown.
Objective: The present study assessed the effect of ventilatory support using proportional
assist ventilation (PAV) on exercise capacity in patients with IPF.
Methods: Ten patients (61.2 9.2 year-old) were submitted to a cardiopulmonary exercise
testing, plethysmography and three submaximal exercise tests (60% of maximum load):
without ventilatory support, with continuous positive airway pressure (CPAP) and PAV. Submax-
imal tests were performed randomly and exercise capacity, cardiovascular and ventilatory
response as well as breathlessness subjective perception were evaluated. Lactate plasmatic
levels were obtained before and after submaximal exercise.
Results: Our data show that patients presented a limited exercise capacity (9.7 3.8 mL O2/
kg/min). Submaximal test was increased in patients with PAV compared with CPAP and without
ventilatory support (respectively, 11.1  8.8 min, 5.6 4.7 and 4.5 3.8 min; p< 0.05). An
improved arterial oxygenation and lower subjective perception to effort was also observed
in patients with IPF when exercise was performed with PAV (p< 0.05). IPF patients performingdicine, University of Sa˜o Paulo, Av. Dr. Arnaldo, 455, 1st Floor, Room 1210, Sa˜o Paulo, 01246-903 SP,
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Effect of PAV on exercise performance in IPF patients 135submaximal exercise with PAV also presented a lower heart rate during exercise, although
systolic and diastolic pressures were not different among submaximal tests. Our results suggest
that PAV can increase exercise tolerance and decrease dyspnoea and cardiac effort in patients
with idiopathic pulmonary fibrosis.
ª 2009 Elsevier Ltd. All rights reserved.Figure 1 A schematic representation of patient’s recruitment.Introduction
Idiopathicpulmonaryfibrosis (IPF) is a specific formofchronic
fibrosing interstitial pneumonia limited to the lung and
associated with the histological appearance of usual inter-
stitial pneumonia on surgical lung biopsy.1 Impaired exercise
performance is a characteristic feature of IPFmainly because
of theheightened sense of dyspnoea and leg fatigue.2,3 These
symptoms are consequent of reduction in pulmonary volume,
increase in lung recoil pressure at a given absolute lung
volume,4 abnormal gas exchange during exercise,5 cardiac
limitations6 and peripheral skeletal muscle abnormalities.7
In an attempt to improve exercise performance and
reduce dyspnoea in patients with chronic lung diseases,
various forms of non-invasive ventilatory support have been
used to assist ventilation during exercise such as: contin-
uous positive airway pressure (CPAP), pressure support
ventilation (PSV) and proportional assist ventilation (PAV).
All these modalities seems to improve exercise perfor-
mance in patients with chronic obstructive pulmonary dis-
eases,8e10 empowering them to make activities that could
not be performed without ventilatory support.
Proportional assist ventilation (PAV) is a newer mode of
partial ventilatory support that has demonstrated superi-
ority when compared with other modalities. For instance,
the PSV and the pressure controlled ventilation (PCV) are
limited by pressure and the respiratory cycle is ended by
flow and time, respectively, what develops a patiente
ventilator asynchrony at rest increasing with effort.11 In
contrast, during PAV, the pressure applied by the ventilator
is proportional to the volume and/or flow required allowing
a better synchrony between patient’s effort and ventilatory
support and improvement comfort and dyspnoea.12,13 This
makes PAV ideally suited to assist ventilation during the
variable ventilatory demands of exercise, which does not
occur with other modalities of ventilatory support.11,14
In COPD patients, PAV has been shown to increase
exercise tolerance in stable patients,15,16 to improve
exercise tolerance and dyspnoea in hypercapnic COPD
patients,17 and to enable a higher intensity of training in
patients with severe COPD, leading to greater improve-
ments in maximum exercise capacity with evidence of true
physiological adaptation.18
Despite of the effects of PAV in COPD patients, to our
knowledge these benefits have never been evaluated in IPF
patients. It should be of particular importance to support
exercise with PAV in these patients because it could deliver
an assisted volume and lending a support to insufflate the
lungs with increased elastances4 and provide ventilatory
autonomy, reducing dyspnoea and allowing higher endur-
ance time. Therefore, the aim of the present study was to
investigate the effect of PAV on exercise tolerance and
breathlessness in IPF patients during submaximal exercise.Methods
Patients
Thirty-seven patients with documented IPF, identified
through clinical records, who attended the Interstitial Lung
Diseases Ambulatory Group as outpatients at a Clinical
Hospital, over a period of 6 months, were invited to
participate in the study. IPF was diagnosed according to
American Thoracic Society/European Respiratory Society
criteria1 and all patients had pulmonary biopsy with the
usual interstitial pneumonia pattern. Twenty-one patients
were excluded mainly due to use of continuous oxygen or
cardiac diseases (Fig. 1). Sixteen eligible patients in clinical
stability (without exacerbations for at least 3 months) were
identified and invited to participate, 4 refused, 12 begun
the study and 10 concluded (1 death and 1 gave up) the
study. All patients were under corticosteroids as regular
treatment and there was no change in medication during
the study. Patients had 61.2 9.2 year-old and body mass
index (BMI) of 30.6 4.2 kg/m2 (Table 1).
They were properly informed about the study objective
and gave their informed consent to participate into the study
which was approved by the Ethics Committee of Hospital.
Study protocol
Patients were invited to be present at hospital in five
separate days. At the first and second days, patients per-
formed pulmonary function and cardiopulmonary exercise
testing on a cycle ergometer. In the 3 subsequent visits, in
Table 1 Demographic, anthropometric and functional
characteristics of the patients in the study.
Characteristics Mean (SD)
Anthropometric
N 10
Sex (M/F) 4/6
Age (yrs) 61.2 (9.2)
Weight (kg) 75.1 (10.5)
Height (cm) 156 (9.0)
BMI (kg/m2) 30.6 (4.2)
Pulmonary function
FVC (L) 2.1 (0.7)
(% pred) 79.2 (24.2)
FEV1 (L) 1.8 (0.6)
(% pred) 85.3 (25.8)
FEV1/FVC (%) 85.2 (4.7)
TLC (L) 3.4 (0.9)
(% pred) 77.2 (14.1)
RV (L) 1.3 (0.2)
(% pred) 78.3 (10.7)
DLCO (mL/min/mmHg) 9.1 (2.5)
(% pred) 45.9 (13.2)
Oximetry at rest (SpO2, %) 94.7 (2.0)
Values are presented as mean SD, with the exception of sex,
which is given as absolute number. M: male; F: female; BMI:
body mass index; FVC: forced vital capacity; FEV1: forced
expiratory volume in 1 s; TLC: total lung capacity; RV: residual
volume; and DLCO: carbon monoxide transfer factor. % pred:
% predicted.
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formed 3 submaximal tests: no support, CPAP and PAV.
Tests were performed in a random order, using sealed
envelopes. Prior to each exercise test, subjects abstained
from food (2 h), caffeinated beverages (4 h) and to any
unusual physical effort. All studies were carried out with
patients breathing room air. All tests were symptom-limited
and during exercise sessions patients cycled at 60 revolu-
tions per minute (ranging from 50 to 70). Exercise tests
were stopped if the patients showed oxyhemoglobin desa-
turation (oxygen saturation <85% e pulse oximetry) (ATS/
ACCP, 2003).19 During the tests, patients were asked their
perceived breathlessness and sensation of leg discomfort
(Borg, 1982)20 by pointing to a number or phrase on a 10-
point Borg scale set in large type on a sheet in front of
them. Before the study, all patients underwent a period
during which it was ensured that they were thoroughly
acquainted with cycling, the breathing equipment, the
facial masks, the ventilator and the Borg scale.
Measurements
Cardiopulmonary exercise testing (CPET)
Cycle ergometer CPET was performed on a digital
computer-based exercise system (Sensormedics, Vmax 229,
USA) with breath-by-breath analysis of metabolic, ventila-
tory, and cardiovascular variables while subjects breathing
by mouthpiece and wearing noseclips. A standard 1 minincremental cycle exercise protocol was performed. After
stabilization and a 3 min period of unloaded pedaling, the
rate of power increment was individually selected to
provide exercise duration of more than 8 and less than
12 min (ramp protocol), how recommended by previous
study.21 The following data were recorded as moving
average of 8 breaths: oxygen uptake (VO2, mL/min STPD),
carbon dioxide production (VCO2, mL/min STPD), respira-
tory exchange ratio (R), minute ventilation (VE, L/min
BTPS), ventilatory equivalent for oxygen and carbon
dioxide (VE/VO2 and VE/VCO2), end-tidal partial pressures
of oxygen and carbon dioxide (PETO2 and PETCO2, mmHg),
and oxygen pulse (VO2/HR, mL/min/beat). VO2 peak was
predicted according to American Heart Association22
according to gender and age as very weak, weak, regular,
good and excellent. VO2 at the anaerobic threshold was
established by the gas exchange method inspecting the
inflection point of VCO2 with respect to VO2 (modified V-
slope) and, secondarily, by the ventilatory method, when
VE/VO2 and PETO2 increased while VE/VCO2 and PETCO2
remained stable, respectively. VO2 at the respiratory
compensation point was defined where VE started to
change out of proportion of VCO2, i.e., systematic increase
in VE/VCO2 with a consequent decline in PETCO2.
23 A 12-
lead ECG was monitored throughout exercise.
Submaximal exercise test
Before cycling, patientswerewithout ventilatory support for
3 min and another 3 min without ventilatory support or with
the modalities PAV or CPAP. Then, patients started cycling
3 min with no load applied. The load was then increased at
60% of maximal load achieved in the incremental test.
Peripheral oxygen saturation (SpO2) and heart rate (HR)were
continuously monitored by pulse oximetry (Onyx 9500,
Nonin, USA), end-tidal carbon dioxide tension (ETCO2) and
respiratory rate (RR) were monitored continuously at the
mask by means of a capnograph (DX-7100, Dixtal, USA), and
blood pressure was measured with the cuff technique and
recorded each minute and at the end of exercise. Lactate
plasmatic levels were obtained before and after submaximal
exercise by a lactimeter (Accusport, Boehringer Mannhein
GmbH, Germany). Tests were performed at the same time of
day to each patient to avoid circadian variation.
Ventilatory settings
Both PAV and CPAP were delivered by ventilator BiPAP
(Vision, Respironics, USA) able to compensate for leaks,
through a face mask (Respironics, USA) with adequate size
for each patient face. All patients were instructed to
breathe through the nose in the mask and to keep the
mouth closed before exercise tests to prevent leaks. During
the exercise, patients breathed spontaneously according to
their ventilatory demand. Briefly, adjustment of PAV entails
levels for volume-related assist (VA) and flow-related assist
(FA) according to the equation of motion.17
PapplZP0 þ E V þ R V 0
where Pappl is the pressure applied to inflate the respiratory
system, P0 is the elastic recoil pressure at the end of the
expiration which is zero if the lung inflation starts from the
elastic equilibriumvolumeof the respiratory system;VandV0
are the inspired volume and flow, respectively, E is the total
Figure 2 Curves of flow (a), volume (b) and airway pressure
(c) in PAV modality. Values are presented in ‘‘y’’ axis (a) flow in
L s1; (b) volume in L; (c) pressure in cmH2O. ‘‘X’’ axis is rep-
resented by time in seconds.
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Therefore, E and R should ideally be known to set PAV
appropriately. Since measurements of E and R are not
routinely performed in patients, they had to be done at the
time of the study. We used the ‘‘run-away’’ method as
described by Younes24 and co-workers.17,18 ‘‘Run-away’’
phenomenon is the continuation of positive pressure after
the end of the patient’s inspiratory effort into the neural
expiration, the moment in which the amount of pressure
delivered by the ventilator exceeds the patient’s elastic
recoil opposing force, producing a inspiratory flow and
a volume after the end of inspiratory muscular effort. Since
a display of the ventilator provided continuous recording of
flow, volume and airway pressure (Paw), through which
occurrence of air leaks was eventually recorded, the ‘‘run-
away’’ phenomenon was observed on that display. To
measure E, FAwas set at 1 cmH2O L
1 s1 whereas VAwas set
at 2 cmH2O L
1, then VA was raised in steps of 2 cmH2O L
1
until the ‘‘run-away’’ phenomenon occurred. The patients’ E
was assumed to be the ‘‘run-away’’ value minus
2 cmH2O L
1. Likewise, R was measured by setting VA and FA
at 2 cmH2O L
1 and 1 cmH2O L
1 s1, respectively, then FA
was raised in steps of 1 cmH2O L
1 s1 until the ‘‘run-away’’
phenomenon occurred. The values of the FA at the ‘‘run-
away’’ minus 1 cmH2O L
1 s1 were assumed to reflect
patients’ flow resistances. Therefore, individual values of E
and Rwere obtained for each patient before setting PAV. PAV
was set at a level corresponding to VA and FA at 60% of the
individual values of E and R. An end-expiratory positive
airway pressure (EPAP) amounting to 4 cmH2O was added to
PAV. Fig. 2 demonstrates curves of flow (a), volume (b) and
airway pressure (c) in PAV modality.25
Pulmonary function tests
Lung volumes and forced vital spirometry (forced vital
capacity (FVC)) were measured with a body plethysmo-
graph (Collins GS II, EUA). The predicted values of pulmo-
nary volumes of Goldman and Becklake (1959),26 and the
spirometry predicted values of Knudson et al. (1983)27 were
used. The carbon monoxide transfer factor (DLCO) was
made by single-breath testing technique and the predicted
values of Gaensler and Smith (1973)28 were used. All the
tests were performed according to American Thoracic
Society/European Respiratory Society.29e31
Statistical analysis
The parametric distribution of data was evaluated using
KolmogoroveSmirnov test. Comparison between variables
was made using one-way analysis of variance (ANOVA) fol-
lowed by HolmeSidak (parametric) or Tukey (non-para-
metric) post-hoc tests. Sigma Stat version 3.01 software
package (San Jose, USA) was used for statistical analysis,
with the level of significance set at p< 0.05.
Results
Ventilatory settings
The E and R values were 12.8 1.0 cmH2O L1 and
3.4 0.5 cmH2O L1 s1, respectively. PAV parameters were7.7 0.6 cmH2O L1 and 2.0 0.3 cmH2O L1 s1 of VA and
FA, respectively.
Demographic, anthropometric and functional
characteristics
Data are presented in Table 1. Ten patients were studied
being 4 with less than 60 years old and 5 were overweight
(BMI> 30 kg/m2). Total lung capacity (TLC) was higher than
80% predicted in 4 patients, between 60 and 80% predicted
in 5 patients, and between 40 and 60% predicted in 1
patient. Seven patients presented IC/TLC <50% predicted
and DLCO was <40% predicted in 3 patients. All patients
presented pulse oximetry at rest over than 90%.
Maximal capacity of exercise
Maximal exercise capacity (Wpeak) was severely impaired in
studied IPF patients and mean Wpeak obtained was
42 14.9W. Maximal aerobic capacity average was
9.79 3.85 mL O2/kg/min and four patients reached
VO2max (plateau); the physiological responses to the
incremental test in different levels of effort are summa-
rized in Table 2. Nine patients presented a very weak
aerobic capacity (6W/3M) and one patient (1M) a weak
aerobic capacity. In 7 patients, O2 pulse was lower than
5 mL O2/beat/min and only 1 patient presented O2 pulse
higher than 10 mL O2/beat/min. Five patients reported
exercise limitation due to leg fatigue and in 5, exercise was
interrupted due to oxygen desaturation (<85%).
Table 2 The physiological responses to the incremental
exercise test in different levels of effort.
Exercise peak Mean (SD)
Load (W) 42 (14.9)
VO2 (mL/kg/min) 9.7 (3.8)
VO2 (% pred) 38.9 (20.5)
HR (% pred) 87.5 (12.5)
VO2/HR (mL O2/beat/min) 5.7 (3.7)
VE/MVV 0.4 (0.1)
Dyspnoea (score) 7.6 (2.5)
RCP
Load (W) 36.5 (17.3)
VO2 (mL/kg/min) 8.8 (2.3)
HR (% peak) 97 (4)
VO2/HR (mL O2/beat/min) 5.1 (2.3)
VE (L/min) 36 (8.7)
AT
Load (W) 17.5 (11.2)
VO2 (mL/kg/min) 6.4 (1.5)
HR (% peak) 88 (5)
VO2/HR (mL O2/beat/min) 4.1 (1.6)
VE (L/min) 26.3 (8.3)
Values are presented as mean SD. AT: anaerobic threshold;
RCP: respiratory compensation point; VO2: oxygen consump-
tion; HR: heart rate; VE: minute ventilation; MVV: maximal
voluntary ventilation; and VO2/HR: O2 pulse.
Figure 3 (A). Endurance time during submaximal exercise
without ventilatory support and with CPAP or PAV modalities in
IPF patients. Values are presented as median and interquartiles
values of endurance times in three conditions; *p< 0.05 when
compared with without ventilatory support (WVS) and CPAP.
(B). Breathlessness perception by IPF patients before and
during submaximal exercise tests with PAV, CPAP or without
ventilatory support. Values are presented as mean SD of
effort subjective perception (Borg Score) before, at each
minute of the submaximal exercise. RZ at rest; 0WZ pedal-
ing with no load; *p< 0.05 when compared with the values
getting without ventilatory support and CPAP.
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PAV and CPAP were well tolerated by all patients. Air leaks,
monitored by means of the display of the ventilator, did not
occur. ‘‘Run-away’’ phenomenon did not occur during the
trials with PAV. CPAP did not improved endurance time
compared with non-ventilatory support (5.6 4.7 min vs.
4.5 3.8 min, respectively). Submaximal exercise with PAV
support improved the endurance time (11.1 8.8 min;
p< 0.05) compared with tests performed without ventila-
tory support exercise or CPAP (Fig. 3A).
Reported breathlessness by IPF patients before and
during submaximal exercise tests was also evaluated
(Fig. 3B). Before exercise, patients presented similar
breathlessness perception (no breathlessness) at rest
(p> 0.05). Patients’ breathlessness perception increased as
soon as they started to pedal with no applied load when
they were not receiving ventilatory support or with CPAP
while the perception remained unchanged with PAV
(0.5 0.0; 0.5 0.0, 0.0 0.0 respectively, p< 0.05). PAV
resulted in reduction in effort perception at the first minute
of loaded exercise in comparison without ventilatory
support exercise or with CPAP (0.0 0.0, 1.0 0.0;
0.5 0.0, respectively; p< 0.05). This reduced breath-
lessness perception remained until the fifth minute (4 2;
4 2 and 3 2, respectively; p< 0.05).
Respiratory and cardiac parameters during the
exercise
The profile of respiratory and cardiac parameters during
the 3 submaximal exercise sessions (without ventilatorysupport and with CPAP or PAV) is represented in Figs. 4 and 5.
At rest, patients presented similar SpO2 at rest
(p> 0.05). Before submaximal exercise test begins (0W),
patients already presented an increase in SpO2 with PAV
when comparedwith exercise performedwithout ventilatory
support or with CPAP (respectively, 96 1%, 95 2% and
95 2%; p< 0.05) (Fig. 4A). During all exercise, oxygen
desaturation was reduced with IPF patients under PAV
support when compared with CPAP or without ventilatory
support and, at the end of exercise, SpO2 of patients exer-
cising with PAV remained at higher levels (respectively,
92 3%, 89 5% and 88 5%; p< 0.05) (Fig. 4A).
Patients’ exhaled end-tidal carbondioxide tension (ETCO2)
at restwas at similar levels in all submaximalexercise sessions
(Fig. 4B). As soon as patients begun to exercise with no load
was applied (0W), IPF patients already presented an increase
Figure 4 (AeB) Profile of respiratory parameters during the
submaximal exercise without ventilatory support and with
CPAP or PAV. Values are presented as mean SD of oxygen
peripheric saturation (SpO2; A) and of exhaled end-tidal carbon
dioxide tension (ETCO2; B), before, at each minute of the
submaximal exercise. RZ at rest; 0WZ pedaling with no load;
*p< 0.05 when compared with the values getting without
ventilatory support and CPAP.
Figure 5 (AeB) Profile of cardiac parameters during the
submaximal exercise without ventilatory support and with
CPAP or PAV. Values are presented as mean SD of double
product (DP; A) and heart rate (HR; B) before, at each minute
of the submaximal exercise. RZ at rest; 0WZ pedaling with
no load; *p< 0.05 and UpZ 0.05.when compared with the
values getting without ventilatory support and CPAP.
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ventilatory support and with CPAP while ETCO2 remained
unchanged when patients performing exercise with PAV
(p< 0.05). The increase in ETCO2 levels was lower when
patients exercised with PAV compared when patients without
ventilatory support or with CPAP and, at the fifth minute
exercise test, ETCO2 was at lower levels in patients perform-
ing exercise with PAV (respectively, 39 5 mmHg,
41 8 mmHg and 42 4 mmHg) (p< 0.05) (Fig. 4B).
The respiratory rate (RR) was similar between patients
while exercising without ventilatory support, with CPAP or
PAV before the exercise begins, at each minute of exercise
until the fifth minute.
Cardiac responses to exercise were also evaluated at
each minute during submaximal exercise. IPF patients pre-
sented a similar double product and heart rate before
exercise and with no load applied in all submaximal exercise
sessions (p> 0.05) (Fig. 5A and B). At first and second
minutes of exercise with PAV, patients presented lower
values of double product and heart rate when compared
with exercise performed without ventilatory support or with
CPAP. After that, cardiac responses were similar among all
submaximal exercise sessions until the end of exercise.
Lactate levels at the end of exercise sessions were
evaluated to establish if the effort levels were similar
during submaximal exercises. It can be observed that, afterexercise, patients without ventilatory support, with CPAP
or PAV presented similar levels of lactate (respectively,
3.6 0.9 mmol/L, 3.3 0.6 mmol/L and 3.6 1.0 mmol/L;
p> 0.05). Without ventilatory support or with CPAP, eight
patients stopped the exercise due to dyspnoea and oxygen
peripheric saturation <85% while in patients with PAV most
patients (60%) interrupted exercise due to leg fatigue (6
patients).
Discussion
This is the first study demonstrating the effects of PAV
during exercise in IPF patients. Our findings show that PAV
was well tolerated and improved exercise performance and
arterial oxygen and reduced perceived exertion in IPF
patients. Nevertheless, our results suggest that PAV
decreases cardiac effort due to exercise in these patients.
Several studies have been performed in an attempt to
improve exercise performance in IPF patients including O2
therapy,2,32 inhalation of morphine33 or anesthetic aero-
sols,34 inhalation of nitric oxide,35 however, none of them
demonstrated effectiveness. Hence, our study proposes
feasible benefits that these patients could get with this
ventilatory support during submaximal exercise.
We cannot compare our results with other in this pop-
ulation, however, the present results extend the observa-
tion of use of PAV during exercise in COPD patients.15e18
These authors found that PAV support during cycle exercise
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study, we observed that PAV doubled submaximal exercise
capacity in patients with IPF reinforcing the benefits of PAV
such as reducing dyspnoea, breathlessness perception and
hypoxemia. However, decreased cardiac effort during
exercise has never been previously observed.
Exercise limitation is a very common symptom reported
by patients with IPF and is attributed to a reduction in gas
exchange, ventilatory capacity, dyspnoea, cardiac limita-
tion and peripheral muscle weakness.1,3,4,6,7,21,39 During
exercise, 20e30% of the exercise-induced widening of the
alveolarearterial O2 gradient may be caused by some
impairment of oxygen diffusion and the arterial O2 pressure
(PaO2) and arterial O2 saturation (SaO2) fall increasing the
ventilatory demand and the workload of the inspiratory
muscles.1 PAV is a ventilatory modality that offers partial
support to patients based on their elastance and resistance
and there is evidences suggesting that it can unload inspi-
ratory muscles and improve respiratory efficiency.24 Thus,
reduction in dyspnoea observed in our study may be
explained due to unloading the inspiratory muscles and/or
reducing ETCO2 (improved respiratory efficiency), capa-
bility to match spontaneous changes in patients’ ventila-
tory demands and pattern (comfort) that has also been
reported in COPD patients.
PAV was associated with significantly lower ETCO2 levels
than cycling during without ventilatory support or with
CPAP (Fig. 4B). As reduced ETCO2 levels were not associated
with changes in respiratory rate, we can suppose that this
occurred due to an improvement in the tidal volume caused
by a better respiratory efficiency. The use of ETCO2
assessment may be criticized, however, we used this
parameter only for monitoring purposes.
It has been claimed that the major advantage of PAV
compared to conventional modes of partial ventilatory
support is represented by its capability to match sponta-
neous changes in patients’ ventilatory demands and
pattern. This should be particularly attractive during
exercise where the breathing pattern changes rapidly to
meet the metabolic requirements.14e16 Interestingly, one
of the most common benefits observed in COPD patients
using PAV is the reduction in dyspnoea and improvement in
the ventilatory capacity.15e18 In our study, PAV also resulted
in reduction in effort perception during all exercise time in
IPF patients (Fig. 3B).
A PAV reduced hypoxemia in IPF patients was also
previously described in COPD patients.16,17 Interestingly,
hypoxemia was the main cause of exercise interruption in
80% of IPF patients without ventilatory support or with
CPAP, however, this occurred only in 40% in our patients
with PAV support (Fig. 4A). A 4% decrease in peripheral
oxygen saturation observed during exercise in our patients
reveals a worst prognosis19,36 and may suggest that studied
population presented moderate to severe disease stage.
In the present study, it was observed a decrease in the
cardiac effort (double product and heart rate) in patients
using PAV support. Although we cannot explain this fact, it
is possible that this reduction was consequent of a reduc-
tion in the inspiratory effort.37 The benefits of PAV during
exercise in the cardiac effort were evaluated only by three
studies in COPD patients, however, no difference was
observed in those patients.15,16,18Study limitation
A 60% of VA and FA settings were used to avoid ‘‘run-way’’
during exercise15e18 however, the level of support offered
may be lower than patients’ demand. The adherence of
patient to a non-invasive ventilatory support depends on his
comfort assuring a higher acceptance.13 In the present study,
none of the patient reported discomfort during PAV support
and we believe that this may also influence the observed
benefits. The subjects and an investigator supervising the
exercise tests were not told which mode of ventilation was
used. However, subjects would have perceived pressure
difference during PAV compared with CPAP or when exer-
cising without ventilatory support. Investigators would have
heard the ventilator noise during PAV. Therefore, true
blinding of subjects and investigators was not possible. Some
authors use sham ventilation, however, previous reports in
the literature have shown that patients presented lower
exercise performance using such circuits.17 In addition,
other investigators consider that sham ventilation signifi-
cantly increases the risk of producing a type 1 error.18
Application of CPAP in the present study was not set
according to the literature. This lack of tailoring could
explain why CPAP was not as efficient as PAV in improving
endurance time and dyspnoea. In contrast, PAV was
tailored to the respiratory mechanics of individual patients.
Therefore, in these circumstances, the difference between
PAV and CPAP might well reflect differences in individual
settings rather than differences between ventilatory
modes. Hence the conclusion that PAV is superior to CPAP to
improve exercise tolerance is not warranted on the basis of
our data. However, our results show that performing
exercise with PAV is better than exercising without venti-
latory support. The present study evaluated a reduced
number of patients (nZ 10) which can limit the detection
of small variation in the studied variables and might be
presented as preliminary findings. However, the amount of
patients in the present study was higher than in the
previous studies evaluating the effect of PAV in COPD
patients.15e18Clinical implications
Our results indicating an increase in endurance time with
PAV may be promising, as this mode might allow the
training stimulus to be increased above that possible in the
absence of mechanical support. Thus, our findings reinforce
those previously observed in COPD patients suggesting that
PAV delivered by portable ventilators can proportionate
a better comfort to patients with ventilatory limitation
suggesting its usefulness during exercise in pulmonary
rehabilitation programmes to improve cardiopulmonary
conditioning.38,39
In conclusion, proportional assist ventilation delivered by
a face mask was able to improve exercise tolerance and
reduce dyspnoea in IPF patients. Potential advantages and
disadvantages of proportional assist ventilation compared to
other modes of partial ventilatory assistances need further
physiological studies. Additional information is also needed
to elucidate the appropriate application of proportional
assist ventilation in respiratory rehabilitation programmes.
Effect of PAV on exercise performance in IPF patients 141Conflict of interest
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